Table 2.
Clinical and Pathological Characteristics of Study Population Grouped Taskwise
| Details | Patients having NAT | Patients having NACT | TN/HER2+ patients having NAT | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Train | Test | Overall | Train | Test | Overall | Train | Test | |
| N | 288 | 144 | 144 | 269 | 135 | 134 | 151 | 76 | 75 |
| Median Age (years) | 49.8 | 47.5 | 48.6 | 46.5 | 49.3 | 45.1 | |||
| Age Range (years) | 24—76 | 25—76 | 24—73 | 24—76 | 25—76 | 24—73 | 24—73 | 25—72 | 24—73 |
| Race | |||||||||
| White | 184 (64%) | 89 (62%) | 95 (66%) | 169 (63%) | 81 (60%) | 88 (66%) | 98 (65%) | 49 (64%) | 49 (65%) |
| Black | 85 (30%) | 49 (34%) | 36 (25%) | 83 (31%) | 48 (36%) | 35 (26%) | 46 (30%) | 25 (33%) | 21 (28%) |
| Other | 16 (6%) | 5 (3%) | 11 (8%) | 15 (6%) | 5 (4%) | 10 (7%) | 7 (5%) | 2 (3%) | 5 (7%) |
| NA | 3 (1%) | 1 (1%) | 2 (1%) | 2 (1%) | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Menopausal Status | |||||||||
| Pre | 158 (55%) | 77 (53%) | 81 (56%) | 155 (58%) | 75 (56%) | 80 (60%) | 89 (59%) | 44 (58%) | 45 (60%) |
| Post | 129 (45%) | 67 (47%) | 62 (43%) | 113 (42%) | 60 (44%) | 53 (40%) | 62 (41%) | 32 (42%) | 30 (40%) |
| NA | 1 (0%) | 0 (0%) | 1 (1%) | 1 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| ER Status | |||||||||
| Positive | 179 (62%) | 88 (61%) | 91 (63%) | 160 (59%) | 79 (59%) | 81 (60%) | 46 (30%) | 22 (29%) | 24 (32%) |
| Negative | 109 (38%) | 56 (39%) | 53 (37%) | 109 (41%) | 56 (41%) | 53 (40%) | 105 (70%) | 54 (71%) | 51 (68%) |
| PR Status | |||||||||
| Positive | 146 (51%) | 71 (49%) | 75 (52%) | 128 (48%) | 62 (46%) | 66 (49%) | 36 (24%) | 18 (24%) | 18 (24%) |
| Negative | 142 (49%) | 73 (51%) | 69 (48%) | 141 (52%) | 73 (54%) | 68 (51%) | 115 (76%) | 58 (76%) | 57 (76%) |
| HER2 Status | |||||||||
| Positive | 73 (25%) | 34 (24%) | 39 (27%) | 72 (27%) | 33 (24%) | 39 (29%) | 73 (48%) | 34 (45%) | 39 (52%) |
| Negative | 215 (75%) | 110 (76%) | 105 (73%) | 197 (73%) | 102 (76%) | 95 (71%) | 78 (52%) | 42 (55%) | 36 (48%) |
| Nottingham Grade | |||||||||
| 1 | 19 (7%) | 9 (6%) | 10 (7%) | 16 (6%) | 9 (7%) | 7 (5%) | 3 (2%) | 1 (1%) | 2 (3%) |
| 2 | 135 (47%) | 74 (51%) | 61 (42%) | 121 (45%) | 66 (49%) | 55 (41%) | 58 (38%) | 33 (43%) | 25 (33%) |
| 3 | 132 (46%) | 61 (42%) | 71 (49%) | 130 (48%) | 60 (44%) | 70 (52%) | 88 (58%) | 42 (55%) | 46 (61%) |
| NA | 2 (1%) | 0 (0%) | 2 (1%) | 2 (1%) | 0 (0%) | 2 (1%) | 2 (1%) | 0 (0%) | 2 (3%) |
| Field Strength | |||||||||
| 1.5T | 133 (46%) | 63 (44%) | 70 (49%) | 124 (46%) | 60 (44%) | 64 (48%) | 67 (44%) | 33 (43%) | 34 (45%) |
| 3T | 155 (54%) | 81 (56%) | 74 (51%) | 145 (54%) | 75 (56%) | 70 (52%) | 84 (56%) | 43 (57%) | 41 (55%) |
| MRI Model | |||||||||
| Avanto1 | 67 (23%) | 30 (21%) | 37 (26%) | 63 (23%) | 28 (21%) | 35 (26%) | 39 (26%) | 18 (24%) | 21 (28%) |
| OptimaMR450w2 | 25 (9%) | 15 (10%) | 10 (7%) | 23 (9%) | 15 (11%) | 8 (6%) | 10 (7%) | 6 (8%) | 4 (5%) |
| Signa Excite2 | 1 (0%) | 0 (0%) | 1 (1%) | 1 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 0 (0%) | 1 (1%) |
| Signa HDx2 | 91 (32%) | 51 (35%) | 40 (28%) | 85 (32%) | 49 (36%) | 36 (27%) | 42 (28%) | 25 (33%) | 17 (23%) |
| Signa HDxt2 | 57 (20%) | 23 (16%) | 34 (24%) | 54 (20%) | 21 (16%) | 33 (25%) | 34 (23%) | 17 (22%) | 17 (23%) |
| Skyra2 | 24 (8%) | 12 (8%) | 12 (8%) | 24 (9%) | 12 (9%) | 12 (9%) | 18 (12%) | 8 (11%) | 10 (13%) |
| Trio1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| TrioTim1 | 23 (8%) | 13 (9%) | 10 (7%) | 19 (7%) | 10 (7%) | 9 (7%) | 7 (5%) | 2 (3%) | 5 (7%) |
| Contrast | |||||||||
| Gadavist3 | 1 (0%) | 1 (1%) | 0 (0%) | 1 0%) | 1 (1%) | 0 (0%) | 1 (1%) | 1 (1%) | 0 (0%) |
| Magnevist3 | 185 (64%) | 92 (64%) | 93 (65%) | 175 (65%) | 87 (64%) | 88 (66%) | 98 (65%) | 51 (67%) | 47 (63%) |
| Multihance4 | 85 (30%) | 46 (32%) | 39 (27%) | 79 (29%) | 43 (32%) | 36 (27%) | 45 (30%) | 22 (29%) | 23 (31%) |
| Unknown | 17 (6%) | 5 (3%) | 12 (8%) | 14 (5%) | 4 (3%) | 10 (7%) | 7 (5%) | 2 (3%) | 5 (7%) |
1
Siemens, Munich, Germany;
2
GE Healthcare, Little Chalfont, UK;
3
Bayer Healthcare, Berlin, Germany;
4
Bracco, Milan, Italy; Age measured in years; NA = information was not available; Grade = Nottingham grade